Abraxane monotherapy is indicated for the treatment of metastatic breast cancer The recommended dose of Abraxane in combination with gemcitabine is Attachment 1: Product information for AusPAR Abraxane paclitaxel (nab) Abraxis PM Date of Finalisation 17 June This Product. Learn more about ABRAXANE®, including dosing, efficacy, and safety information. This site is intended for US healthcare professionals only.
|Published (Last):||20 December 2012|
|PDF File Size:||19.40 Mb|
|ePub File Size:||3.83 Mb|
|Price:||Free* [*Free Regsitration Required]|
Nab-paclitaxel was well tolerated, with the primary toxicity being mild sensory neuropathy. Support Center Support Center.
Data were collected retrospectively on a select group of patients who received nab-paclitaxel if they had private insurance coverage or met the eligibility criteria for the Ontario New Drug Funding Program, creating a potential for selection bias. Current line of chemotherapy for advanced disease [median range ].
ABRAXANE – Prescribing Information
Phase iii trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil—based paclitaxel in women with breast cancer. Journal List Curr Oncol v.
That trial will evaluate the relationships of sparc overexpression and of changes in blood levels of caveolin 1 with progression-free survival and secondary endpoints of response during treatment. In addition, it has been suggested that the Cremophor solvent used in the preparation of paclitaxel may have a direct negative effect on the antitumour properties of that drug Women who received nab-paclitaxel qw had a median overall survival of Footnotes a Abraxis BioScience, data on file. J Clin Oncol ; Find articles by M.
Retrospective data obtained included demographics, disease characteristics, prior chemotherapy, nab-paclitaxel treatment, toxicity, and survival.
Grade 2 fatigue was reported in 4 patients 9. Pu crossover abeaxane study of solvent-based paclitaxel and nab-paclitaxel.
Find articles by S. Those results differ from the findings reported from abrxxane phase iii trial by Gradishar et al. This article has been cited by other articles in PMC.
Those observations suggest that nab-paclitaxel may provide long-term disease control in the difficult-to-treat taxane-refractory mbc population. More than twice as many abfaxane reductions occurred in the nab-paclitaxel q3w group The results of a randomized phase ii study in women with mbc suggest that weekly dosing of nab-paclitaxel qw: The optimal dose and schedule of nab-paclitaxel has yet to be clearly defined.
Cremophor EL—mediated alteration of paclitaxel distribution in human blood: Women receiving nab-paclitaxel had a median overall survival of Median duration of therapy was 5.
Author information Copyright and License information Disclaimer. Median survivals were 7.
ABRAXANE | Full Prescribing Information
Table i summarizes patient demographics and treatment characteristics. Regardless of the schedule of administration, women abgaxane experienced clinical benefit from nab-paclitaxel lived significantly longer than those who did not achieve clinical benefit [ Cancer and Leukemia Group B trial Steroid premedication was not required before administration of therapy.
Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: Paclitaxel and docetaxel are both hydrophobic, and to enable intravenous administration, they are formulated using the synthetic solvents polyoxyethylated castor oil Cremophor EL: Median survivals were Radiologic and clinical assessments were performed at the discretion of the treating physician.
Clinical benefit was achieved in 24 patients Peripheral abraxanee induced by paclitaxel: The remaining authors have no financial conflicts of interest to disclose. Clinical benefit was based on clinical and radiologic assessments for example, computed tomography imaging of patients, which were requested by the treating physicians at variable points in time. In the Cox proportional hazards analysis, achievement ip clinical benefit hr: Find articles by N.
Traditional solvent-based taxanes have been shown to be abraxanne in the treatment of mbc. Albumin-bound paclitaxel ab-pac versus docetaxel for first-line treatment of metastatic breast cancer mbc: